Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.

Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH.

BJU Int. 2010 Nov;106(9):1270-6. doi: 10.1111/j.1464-410X.2010.09357.x.

2.

Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.

Tomita Y.

Int J Urol. 2016 Jan;23(1):13-21. doi: 10.1111/iju.12899. Epub 2015 Sep 7. Review.

3.

[Treatment of locally advanced renal tumors].

Sánchez Zalabardo D, Millán Serrano JA, De Pablo Cárdenas A, Cuesta Alcalá JA.

Actas Urol Esp. 2010 Feb;34(2):134-41. Review. Spanish.

PMID:
20403277
4.

[Conservative parenchymal surgery in kidney neoplasms].

Martínez-Piñeiro JA, López-Tello J, Martínez-Piñeiro L, de la Peña JJ.

Actas Urol Esp. 2000 Feb;24(2):94-119. Review. Spanish.

PMID:
10829441
5.

Sunitinib therapy in renal cell carcinoma.

O'Brien MF, Russo P, Motzer RJ.

BJU Int. 2008 Jun;101(11):1339-42. doi: 10.1111/j.1464-410X.2008.07506.x. Epub 2008 Feb 18. Review. No abstract available.

6.

Predicting cancer-control outcomes in patients after nephron sparing surgery.

Zigeuner R, Pummer K.

Arch Ital Urol Androl. 2009 Jun;81(2):91-5. Review.

PMID:
19760863
7.

[Results of nephron-sparing surgery for renal cell carcinoma of more than 4 cm in diameter].

Peycelon M, Vaessen C, Misraï V, Comperat E, Conort P, Bitker MO, Haertig A, Chartier-Kastler E, Richard F, Rouprêt M.

Prog Urol. 2009 Feb;19(2):69-74. doi: 10.1016/j.purol.2008.10.010. Epub 2008 Nov 29. Review. French.

PMID:
19168008
8.

Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.

Ito T, Kutikov A.

Nat Rev Urol. 2015 Feb;12(2):69-70. doi: 10.1038/nrurol.2014.356. Epub 2015 Jan 20. Review. No abstract available.

PMID:
25600094
9.

Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.

Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A.

Urology. 2013 Jan;81(1):111-5. doi: 10.1016/j.urology.2012.09.014. Epub 2012 Nov 13. Review.

PMID:
23153934
10.

Do targeted agents offer clinical benefit as presurgical therapy?

Bex A, Haanen J.

World J Urol. 2014 Feb;32(1):3-8. doi: 10.1007/s00345-013-1041-3. Epub 2013 Feb 26. Review.

PMID:
23440338
11.

[The role of therapies in the treatment of small renal masses].

Vázquez-Alonso F, Puche-Sanz I, Flores Martín J, Martínez-Morcillo A, Vicente-Prados FJ, Cózar-Olmo JM.

Arch Esp Urol. 2013 Jan-Feb;66(1):186-91. Review. Spanish.

PMID:
23406815
12.

Is there an emerging role for neoadjuvant targeted therapy in renal cell carcinoma?

Maruschke M, Hakenberg OW.

Minerva Urol Nefrol. 2009 Jun;61(2):109-14. Review.

PMID:
19451892
13.

Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?

Shahait M, Mukherji D, El-Hout Y.

Indian J Urol. 2015 Apr-Jun;31(2):102-5. doi: 10.4103/0970-1591.154300. Review.

14.

Current Status of Nephron-Sparing Surgery (NSS) in the Management of Renal Tumours.

Venkatramani V, Swain S, Satyanarayana R, Parekh DJ.

Indian J Surg Oncol. 2017 Jun;8(2):150-155. doi: 10.1007/s13193-016-0587-0. Epub 2017 Jan 30. Review.

PMID:
28546710
15.

Neoadjuvant therapy for localized and locally advanced renal cell carcinoma.

Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, Campbell SC, Rini BI, Derweesh IH.

Urol Oncol. 2017 Aug 9. pii: S1078-1439(17)30377-0. doi: 10.1016/j.urolonc.2017.07.015. [Epub ahead of print] Review.

PMID:
28802883

Supplemental Content

Support Center